Avalo Therapeutics Inc
F:C6K0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Avalo Therapeutics Inc
F:C6K0
|
US |
|
G
|
Globant SA
LSE:0RIX
|
LU |
|
H
|
Hormel Foods Corp
XMUN:HO7
|
US |
|
A
|
Anika Therapeutics Inc
F:AKP
|
US |
|
S
|
Swedbank AB
XBER:FRYA
|
SE |
|
Vail Resorts Inc
NYSE:MTN
|
US |
|
A
|
American Aires Inc
F:A5A
|
CA |
|
S
|
SSE PLC
F:SCT
|
UK |
|
Delta Dunia Makmur Tbk PT
IDX:DOID
|
ID |
|
Aegon NV
OTC:AEGOF
|
NL |
|
W
|
Weibo Corp
XMUN:2WBA
|
CN |
Wall St Price Targets
C6K0 Price Targets Summary
Avalo Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for C6K0 is 33.85 EUR with a low forecast of 24.67 EUR and a high forecast of 45.27 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is C6K0's stock price target?
Price Target
33.85
EUR
According to Wall Street analysts, the average 1-year price target for C6K0 is 33.85 EUR with a low forecast of 24.67 EUR and a high forecast of 45.27 EUR.
What is the Revenue forecast for Avalo Therapeutics Inc?
Projected CAGR
227%
Over the last 13 years, the compound annual growth rate for Revenue has been -2%. The projected CAGR for the next 8 years is 227%.
What is the Gross Profit forecast for Avalo Therapeutics Inc?
Projected CAGR
221%
The compound annual growth rate for Gross Profit over the next 8 years is 221%.
